A pilot study of the pharmacokinetics and triglyceride lowering activity of acipimox in dialyzed uremic patients.

Abstract

The pharmacokinetics of acipimox was studied in 6 dialyzed uremic patients given single oral doses of 50 mg. Acipimox was not significantly eliminated outside dialysis, whereas during dialysis it was efficiently cleared with plasma, t 1/2 is about 2.6 hours. Accordingly, a dosage schedule of 50 mg or 100 mg of acipimox after each dialysis session was selected for a second, 4-week study in 14 uremic patients with hypertriglyceridemia. Acipimox plasma levels, monitored during the study, proved in agreement with those expected on a theoretical pharmacokinetic basis. A clear-cut reduction of serum triglyceride levels was also achieved.

• Authors: A Bonadonna, C Cascone, G Munaretto, M De Luca, R Bruno, E Maggi, V Tamassia
• Journal: International journal of clinical pharmacology, therapy, and toxicology (Int J Clin Pharmacol Ther Toxicol) Vol. 23 Issue 2 Pg. 112-4 (Feb 1985) ISSN: 0174-4879 [Print] Germany
• PMID: 3988395 (Publication Type: Journal Article)

Chemical References

• Hypolipidemic Agents
• Pyrazines
• Triglycerides
• acipimox

Topics

• Adult
• Aged
• Female
• Humans
• Hypolipidemic Agents (administration & dosage, metabolism)
• Kinetics
• Male
• Middle Aged
• Pilot Projects
• Pyrazines (administration & dosage, metabolism)
• Renal Dialysis
• Time Factors
• Triglycerides (metabolism)
• Uremia (metabolism)